![Paul Firuta](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Paul Firuta
Directeur des opérations chez
IEcure, Inc.
Profil
Paul Firuta currently works at iECURE, Inc., as Chief Operating Officer from 2021.
Mr. Firuta also formerly worked at OraPharma, Inc., as Director-National Accounts & Reimbursement from 2000 to 2006, NPS Pharmaceuticals, Inc., as President-US Commercial Operations from 2014 to 2015, Shire ViroPharma, Inc., as Vice President & & General Manager-Americas from 2008 to 2014, Achillion Pharmaceuticals, Inc., as Chief Operating Officer & Executive Vice President from 2018 to 2020, Bioblast Pharma Ltd., as Chief Commercial Officer from 2015 to 2016, Lev Pharmaceuticals, Inc., as Vice President-Managed Markets from 2006 to 2008, and uniQure NV, as Chief Commercial Officer from 2016 to 2018.
Mr. Firuta received his undergraduate degree from King's College (Pennsylvania) and Masters Business Admin degree from St. Joseph's University.
Postes actifs de Paul Firuta
| Sociétés | Poste | Début |
|---|---|---|
IEcure, Inc.
 IEcure, Inc. BiotechnologyHealth Technology Operates as a a clinical-stage biotechnology company that develops in-vivo gene insertion/editing therapies to treat rare liver disorders | Directeur des opérations | 01/02/2021 |
Anciens postes connus de Paul Firuta
| Sociétés | Poste | Fin |
|---|---|---|
| ACHILLION PHARMACEUTICALS, INC. | Directeur des opérations | 28/01/2020 |
| UNIQURE N.V. | Corporate Officer/Principal | 01/06/2018 |
Bioblast Pharma Ltd.
 Bioblast Pharma Ltd. BiotechnologyHealth Technology Operates as a biopharmaceutical company | Corporate Officer/Principal | 01/05/2016 |
| NPS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/02/2015 |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Corporate Officer/Principal | 01/02/2014 |
Formation de Paul Firuta
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
59
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for bone and mineral disorders | Health Technology |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs | Health Technology |
OraPharma, Inc.
 OraPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces drugs for oral diseases | Health Technology |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases | Health Technology |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
King's College (Pennsylvania)
 King's College (Pennsylvania) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St. Joseph's University
 St. Joseph's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lev Pharmaceuticals, Inc.
 Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutic products for the treatment of inflammatory diseases | Health Technology |
uniQure NV
 uniQure NV BiotechnologyHealth Technology Engages in the discovery, development and commercialization of gene therapies products | Health Technology |
IEcure, Inc.
IEcure, Inc. BiotechnologyHealth Technology Operates as a a clinical-stage biotechnology company that develops in-vivo gene insertion/editing therapies to treat rare liver disorders | Health Technology |
